Evidence map›Paper›PMID 33853758›Full record

ArticleThe Journal of biological chemistry

The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1.

Lee D Harris, Janic Le Pen, Nico Scholz, Juliusz Mieszczanek, Natalie Vaughan, Simon Davis, Georgina Berridge, Benedikt M Kessler, Mariann Bienz, Julien D F Licchesi

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. From seeds to trees: how E2 enzymes grow ubiquitin chains.Biochemical Society transactions · 2023
    Review
  13. Assembly and disassembly of branched ubiquitin chains.Frontiers in molecular biosciences · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Tools for Decoding Ubiquitin Signaling in DNA Repair.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lee D HarrisDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.
Janic Le PenMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Nico ScholzDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.
Juliusz MieszczanekMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Natalie VaughanDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom.
Simon DavisTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Georgina BerridgeTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Benedikt M KesslerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Mariann BienzMRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Julien D F LicchesiDepartment of Biology and Biochemistry, University of Bath, Bath, United Kingdom. Electronic address: j.licchesi@bath.ac.uk.
University of Bath · GBMRC Laboratory of Molecular Biology · GBUniversity of Oxford · GB

Funding

Medical Research Council U105192713
6 · The paper itself

Abstract

Ubiquitin is a versatile posttranslational modification, which is covalently attached to protein targets either as a single moiety or as a ubiquitin chain. In contrast to K48 and K63-linked chains, which have been extensively studied, the regulation and function of most atypical ubiquitin chains are only starting to emerge. The deubiquitinase TRABID/ZRANB1 is tuned for the recognition and cleavage of K29 and K33-linked chains. Yet, substrates of TRABID and the cellular functions of these atypical ubiquitin signals remain unclear. We determined the interactome of two TRABID constructs rendered catalytic dead either through a point mutation in the catalytic cysteine residue or through removal of the OTU catalytic domain. We identified 50 proteins trapped by both constructs and which therefore represent candidate substrates of TRABID. The E3 ubiquitin ligase HECTD1 was then validated as a substrate of TRABID and used UbiCREST and Ub-AQUA proteomics to show that HECTD1 preferentially assembles K29- and K48-linked ubiquitin chains. Further in vitro autoubiquitination assays using ubiquitin mutants established that while HECTD1 can assemble short homotypic K29 and K48-linked chains, it requires branching at K29/K48 in order to achieve its full ubiquitin ligase activity. We next used transient knockdown and genetic knockout of TRABID in mammalian cells in order to determine the functional relationship between TRABID and HECTD1. This revealed that upon TRABID depletion, HECTD1 is readily degraded. Thus, this study identifies HECTD1 as a mammalian E3 ligase that assembles branched K29/K48 chains and also establishes TRABID-HECTD1 as a DUB/E3 pair regulating K29 linkages.

Indexed as

ProteomicsAmino Acid SequenceAnimalsChlorocebus aethiopsCOS CellsDogsEndopeptidasesHEK293 CellsHumansMadin Darby Canine Kidney CellsPoint MutationProteolysisSignal TransductionSubstrate SpecificityUbiquitinUbiquitinationEndopeptidasesHECTD1 protein, humanUbiquitinUbiquitin-Protein LigasesZRANB1 protein, humandeubiquitinationE3 ubiquitin ligaseHECTD1K29/K48-linked polyubiquitin chainpolyubiquitin chainprotein degradationTRABIDubiquitinubiquitin thioesterase

Identifiers

PMID33853758
PMCPMC7948964
OpenAlexW3116800993

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.